(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Aspen Group, Heska Corporation, and Heron Therapeutics .

The three biggest losers today are AMC, Remark Holdings, and Virgin Galactic.

Winners today

1. Aspen Group (ASPU) – 51.32%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group rising 51.32% to $0.07 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ slid 0.52% to $12,126.33, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.383.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.28%.

More news about Aspen Group.

2. Heska Corporation (HSKA) – 20.61%

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Additionally, the company provides a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.

NASDAQ ended the session with Heska Corporation rising 20.61% to $117.74 on Tuesday, after five consecutive sessions in a row of gains. NASDAQ slid 0.52% to $12,126.33, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Heska Corporation has a trailing twelve months EPS of $-1.66.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.85%.

More news about Heska Corporation.

3. Heron Therapeutics (HRTX) – 17.88%

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

NASDAQ ended the session with Heron Therapeutics rising 17.88% to $1.78 on Tuesday, following the last session’s upward trend. NASDAQ dropped 0.52% to $12,126.33, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Heron Therapeutics has a trailing twelve months EPS of $-2.504.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -306.88%.

Sales Growth

Heron Therapeutics ‘s sales growth is 30.2% for the ongoing quarter and 31.4% for the next.

Yearly Top and Bottom Value

Heron Therapeutics ‘s stock is valued at $1.78 at 17:32 EST, way under its 52-week high of $6.38 and way higher than its 52-week low of $1.48.

Volume

Today’s last reported volume for Heron Therapeutics is 9197020 which is 413.29% above its average volume of 1791750.

More news about Heron Therapeutics .

4. U.S. Gold Corp (USAU) – 10.5%

U.S. Gold Corp. engages in the exploration and development of gold and precious metals in the United States. It also explores for copper and silver deposits. The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 650 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 87 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho. It also has earn-in agreement to acquire a 50% ownership interest in the Maggie Creek project that consists of 103 unpatented mining claims covering approximately 3 square miles in Eureka County, Nevada. The company is based in Elko, Nevada.

NASDAQ ended the session with U.S. Gold Corp jumping 10.5% to $7.05 on Tuesday, after two consecutive sessions in a row of gains. NASDAQ fell 0.52% to $12,126.33, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, U.S. Gold Corp has a trailing twelve months EPS of $-4.37.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.57%.

More news about U.S. Gold Corp.

5. Xenetic Biosciences (XBIO) – 7.49%

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences rising 7.49% to $0.44 on Tuesday while NASDAQ fell 0.52% to $12,126.33.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.85%.

Volume

Today’s last reported volume for Xenetic Biosciences is 3073 which is 94.73% below its average volume of 58375.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Xenetic Biosciences’s stock is considered to be overbought (>=80).

Moving Average

Xenetic Biosciences’s value is way below its 50-day moving average of $0.51 and way under its 200-day moving average of $0.59.

Yearly Top and Bottom Value

Xenetic Biosciences’s stock is valued at $0.44 at 17:32 EST, way below its 52-week high of $1.25 and way higher than its 52-week low of $0.24.

More news about Xenetic Biosciences.

6. iShares FTSE EPRA/NAREIT Europe (IFEU) – 7.21%

NASDAQ ended the session with iShares FTSE EPRA/NAREIT Europe jumping 7.21% to $35.08 on Tuesday while NASDAQ slid 0.52% to $12,126.33.

Earnings Per Share

As for profitability, iShares FTSE EPRA/NAREIT Europe has a trailing twelve months EPS of $3.47.

More news about iShares FTSE EPRA/NAREIT Europe.

7. Kinross Gold (KGC) – 6.69%

Kinross Gold Corporation, together with its subsidiaries, engages in the acquisition, exploration, and development of gold properties principally in the United States, the Russian Federation, Brazil, Chile, Ghana, and Mauritania. It is also involved in the extraction and processing of gold-containing ores; reclamation of gold mining properties; and production and sale of silver. Kinross Gold Corporation was founded in 1993 and is headquartered in Toronto, Canada.

NYSE ended the session with Kinross Gold rising 6.69% to $5.08 on Tuesday while NYSE slid 0.73% to $15,374.11.

Earnings Per Share

As for profitability, Kinross Gold has a trailing twelve months EPS of $1.06.

PE Ratio

Kinross Gold has a trailing twelve months price to earnings ratio of 4.79. Meaning, the purchaser of the share is investing $4.79 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.94%.

More news about Kinross Gold.

8. Hudson Global (HSON) – 6.65%

Hudson Global, Inc. provides talent solutions for mid-to-large-cap multinational companies and government agencies under the Hudson RPO brand in the Americas, the Asia Pacific, and Europe. It offers recruitment process outsourcing (RPO) services, such as complete recruitment outsourcing, project-based outsourcing, contingent workforce solutions, and recruitment consulting for clients' permanent staff hires; and RPO contracting services, including outsourced professional contract staffing and managed services. The company was formerly known as Hudson Highland Group, Inc. and changed its name to Hudson Global, Inc. in April 2012. Hudson Global, Inc. was founded in 1999 and is headquartered in Old Greenwich, Connecticut.

NASDAQ ended the session with Hudson Global rising 6.65% to $23.75 on Tuesday, after two successive sessions in a row of gains. NASDAQ slid 0.52% to $12,126.33, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Hudson Global has a trailing twelve months EPS of $-0.43.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.56%.

Sales Growth

Hudson Global’s sales growth is negative 3.4% for the ongoing quarter and negative 4% for the next.

Volume

Today’s last reported volume for Hudson Global is 4662 which is 48.21% below its average volume of 9003.

Moving Average

Hudson Global’s worth is under its 50-day moving average of $24.30 and way under its 200-day moving average of $28.74.

More news about Hudson Global.

9. Lyft (LYFT) – 5.35%

Lyft, Inc. operates a peer-to-peer marketplace for on-demand ridesharing in the United States and Canada. The company operates multimodal transportation networks that offer riders personalized and on-demand access to various mobility options. It provides Ridesharing Marketplace, which connects drivers with riders; Express Drive, a flexible car rentals program for drivers; Lyft Rentals that provides vehicles for long-distance trips; and a network of shared bikes and scooters in various cities to address the needs of riders for short trips. The company also integrates third-party public transit data into the Lyft app to offer riders various transportation options. In addition, it offers access to autonomous vehicles; centralized tools and enterprise transportation solutions, such as concierge transportation solutions for organizations; Lyft Pink subscription plans; Lyft Pass commuter programs; first-mile and last-mile services; and university safe rides programs. The company was formerly known as Zimride, Inc. and changed its name to Lyft, Inc. in April 2013. Lyft, Inc. was incorporated in 2007 and is headquartered in San Francisco, California.

NASDAQ ended the session with Lyft jumping 5.35% to $9.56 on Tuesday while NASDAQ slid 0.52% to $12,126.33.

Earnings Per Share

As for profitability, Lyft has a trailing twelve months EPS of $-5.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -109.07%.

Volatility

Lyft’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.96%, a negative 0.30%, and a positive 3.95%.

Lyft’s highest amplitude of average volatility was 1.59% (last week), 2.90% (last month), and 3.95% (last quarter).

More news about Lyft.

10. Kentucky First Federal Bancorp (KFFB) – 5.19%

Kentucky First Federal Bancorp operates as the holding company for First Federal Savings and Loan Association of Hazard, and Frankfort First Bancorp, Inc. that provide various banking products and services in Kentucky. Its deposit products include passbook savings and certificate accounts, checking accounts, and individual retirement accounts. The company's loan portfolio comprises one-to four-family residential mortgage loans; construction loans; mortgage loans secured by multi-family property; nonresidential loans that are secured by commercial office buildings, churches, and properties used for other purposes; commercial non-mortgage loans; and consumer loans, such as home equity lines of credit, loans secured by savings deposits, automobile loans, and unsecured or personal loans. In addition, it invests in mortgage-backed securities; and provides insurance products and services. It operates through seven banking offices. The company was incorporated in 2005 and is based in Hazard, Kentucky.

NASDAQ ended the session with Kentucky First Federal Bancorp rising 5.19% to $6.57 on Tuesday, following the last session’s upward trend. NASDAQ dropped 0.52% to $12,126.33, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Kentucky First Federal Bancorp has a trailing twelve months EPS of $0.15.

PE Ratio

Kentucky First Federal Bancorp has a trailing twelve months price to earnings ratio of 43.83. Meaning, the purchaser of the share is investing $43.83 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.47%.

More news about Kentucky First Federal Bancorp.

Losers Today

1. AMC (AMC) – -23.87%

AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. As of March 1, 2022, it operated approximately 950 theatres and 10,600 screens. The company was founded in 1920 and is headquartered in Leawood, Kansas.

NYSE ended the session with AMC sliding 23.87% to $3.89 on Tuesday while NYSE slid 0.73% to $15,374.11.

AMC entertainment stock news: AMC loses 24%, APE gains 18% following conversion settlementThe agreement means that AMC can now move forward with expanding the limit on its pre-split common shares from 524,173,073 to 550,000,000 shares of Class A common stock and its plan to effect a 1-for-10 reverse stock split. , However, based on thepost-conversion/post-reverse stock split total share count of 156,260,885 AMC shares listed in the filing, the58.8 million shares of original common stockwill be joined by 97,420,080 shares coverted from the APE units.

Earnings Per Share

As for profitability, AMC has a trailing twelve months EPS of $-39.152.

Volume

Today’s last reported volume for AMC is 87180300 which is 143.13% above its average volume of 35857300.

Revenue Growth

Year-on-year quarterly revenue growth grew by 26.9%, now sitting on 4.09B for the twelve trailing months.

Previous days news about AMC

• : AMC stock plunges 22% after company agrees to settlement terms, opening up for APE conversion. According to MarketWatch on Monday, 3 April, "The terms of the settlement would open the way for AMC’s proposal to convert its AMC Preferred Equity, or APE , units into shares of common stock, alongside a 10-to-1 reverse stock split and the capacity to sell more shares, which shareholders supported in mid-March but had faced court proceedings. "
• : AMC stock plunges 25% after company agrees to settlement terms, opening up for APE conversion. According to MarketWatch on Monday, 3 April, "The terms of the settlement would open the way for AMC’s proposal to convert its AMC Preferred Equity, or APE , units into shares of common stock, alongside a 10-to-1 reverse stock split and the capacity to sell more shares, which shareholders supported in mid-March but had faced court proceedings. "
• AMC stock plunges 25% after company agrees to stock-conversion settlement. According to MarketWatch on Monday, 3 April, "The terms of the settlement would open the way for AMC’s proposal to convert its AMC Preferred Equity, or APE , units into shares of common stock, alongside a 10-to-1 reverse stock split and the capacity to sell more shares, which shareholders supported in mid-March but had faced court proceedings. "

More news about AMC.

2. Remark Holdings (MARK) – -17.57%

Remark Holdings, Inc. primarily focuses on the development and deployment of artificial-intelligence-based solutions for businesses and software developers. It owns and operates an e-commerce digital media property focuses on a luxury beach lifestyle. The company sells its AI-based products and services under the Remark AI brand in the United States; and under the KanKan brand in China. The company was incorporated in 2006 and is headquartered in Las Vegas, Nevada.

NASDAQ ended the session with Remark Holdings sliding 17.57% to $1.22 on Tuesday while NASDAQ dropped 0.52% to $12,126.33.

Earnings Per Share

As for profitability, Remark Holdings has a trailing twelve months EPS of $-9.07.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -315.25%.

Moving Average

Remark Holdings’s value is way below its 50-day moving average of $1.40 and way under its 200-day moving average of $2.71.

More news about Remark Holdings.

3. Virgin Galactic (SPCE) – -11.73%

Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico. Virgin Galactic Holdings, Inc. was a former subsidiary of Virgin Orbit Holdings, Inc.

NYSE ended the session with Virgin Galactic sliding 11.73% to $3.43 on Tuesday while NYSE fell 0.73% to $15,374.11.

Earnings Per Share

As for profitability, Virgin Galactic has a trailing twelve months EPS of $-1.552.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -54.33%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 70.3%, now sitting on 1.58M for the twelve trailing months.

Yearly Top and Bottom Value

Virgin Galactic’s stock is valued at $3.43 at 17:32 EST, way below its 52-week high of $11.25 and above its 52-week low of $3.24.

Moving Average

Virgin Galactic’s worth is way under its 50-day moving average of $4.94 and way under its 200-day moving average of $5.62.

More news about Virgin Galactic.

4. VerifyMe (VRME) – -9.36%

VerifyMe, Inc., together with its subsidiary, PeriShip Global, LLC, operates as a technology solutions provider that specializes in products to connect brands with consumers and providing brands with end-to-end logistics management for their products. The company operates through two segments, VerifyMe Solutions and PeriShip Global Solutions. The VerifyMe Solutions segment offers technology solutions to connect brands with consumers allowing brand owners the ability to gather business intelligence while engaging directly with their consumers. Its solutions provide brand protection and supply chain functions, such as counterfeit prevention, authentication, serialization, and track and trace features for labels, packaging, and products. This segment also offers consumer engagement capabilities, custom printing of tamper evident labels, utilizing visible and invisible variable codes, and images printed with its proprietary inks. The PeriShip Global Solutions segment offers predictive analytics for optimizing delivery of time and temperature sensitive perishable products. This segment's products include PeriTrack customer dashboard, an integrated web portal tool gives its customers an in-depth look at their shipping activities based on real-time data. It also provides call center, pre-transit, post-delivery, and weather/traffic services. The company has a strategic partnership with INX International Ink Company. The company was formerly known as LaserLock Technologies, Inc. and changed its name to VerifyMe, Inc. in July 2015. VerifyMe, Inc. was incorporated in 1999 and is headquartered in Rochester, New York.

NASDAQ ended the session with VerifyMe dropping 9.36% to $1.84 on Tuesday, after three successive sessions in a row of gains. NASDAQ slid 0.52% to $12,126.33, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, VerifyMe has a trailing twelve months EPS of $-1.483.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.7%.

Moving Average

VerifyMe’s worth is higher than its 50-day moving average of $1.77 and way above its 200-day moving average of $1.54.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VerifyMe’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 1638.3%, now sitting on 10.13M for the twelve trailing months.

More news about VerifyMe.

5. Infinity Pharmaceuticals (INFI) – -8.5%

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Infinity Pharmaceuticals falling 8.5% to $0.15 on Tuesday, after four consecutive sessions in a row of losses. NASDAQ fell 0.52% to $12,126.33, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Infinity Pharmaceuticals has a trailing twelve months EPS of $-0.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3521.35%.

Sales Growth

Infinity Pharmaceuticals’s sales growth is negative 8% for the present quarter and 2% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 20.4%, now sitting on 2.59M for the twelve trailing months.

Yearly Top and Bottom Value

Infinity Pharmaceuticals’s stock is valued at $0.15 at 17:32 EST, way below its 52-week high of $1.76 and above its 52-week low of $0.14.

More news about Infinity Pharmaceuticals.

6. POSCO (PKX) – -8.1%

POSCO Holdings Inc., together with its subsidiaries, manufactures and sells steel rolled products and plates in South Korea and internationally. It operates through four segments: Steel, Construction, Trading, and Others. The company offers hot and cold rolled steel, steel plates, wire rods, galvanized sheets, electrical steel, stainless steel, and titanium. It also engages in the design, manufacture, and construction of steel mills and their facilities, and commercial and residential facilities; export and import of raw materials, as well as provision of supply and purchase transactions between domestic and foreign companies, and various steel products; power generation activities; and provision of network, system integration, and logistics services. In addition, the company is involved in the engineering and construction; research and consulting; architectural design and supervision; investment in venture, energy, and technology industries; electronic commerce; intellectual property services and consulting; transporting and warehousing; real estate development, rental, sale, and management; and education and real estate business. Further, it engages in the resource development; mine development; business facility maintenance; fuel cell; iron ore and coal sales; anode reproduction; and cargo handling business, as well as operates housing business agency. Additionally, the company is involved in the IT service and DVR; electric control engineering; forest resources development; refractory materials sales and furnace maintenance; quicklime manufacturing and sales; wastewater treatment operation and maintenance; rice processing; grain sales; and social enterprise businesses. POSCO Holdings Inc. was incorporated in 1968 and is headquartered in Pohang, South Korea.

NYSE ended the session with POSCO sliding 8.1% to $67.84 on Tuesday, after five consecutive sessions in a row of gains. NYSE fell 0.73% to $15,374.11, after five sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, POSCO has a trailing twelve months EPS of $4.5.

PE Ratio

POSCO has a trailing twelve months price to earnings ratio of 15.09. Meaning, the purchaser of the share is investing $15.09 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.41%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, POSCO’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for POSCO is 476603 which is 122.53% above its average volume of 214168.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.5%, now sitting on 86.84T for the twelve trailing months.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jun 28, 2022, the estimated forward annual dividend rate is 2.65 and the estimated forward annual dividend yield is 4.41%.

More news about POSCO.

7. Valero Energy (VLO) – -8.09%

Valero Energy Corporation manufactures, markets, and sells transportation fuels and petrochemical products in the United States, Canada, the United Kingdom, Ireland, and internationally. The company operates through three segments: Refining, Renewable Diesel, and Ethanol. It produces conventional, premium, and reformulated gasolines; gasoline meeting the specifications of the California Air Resources Board (CARB); diesel fuels, and low-sulfur and ultra-low-sulfur diesel fuels; CARB diesel; other distillates; jet fuels; blendstocks; and asphalts, petrochemicals, lubricants, and other refined petroleum products, as well as sells lube oils and natural gas liquids. As of December 31, 2021, the company owned 15 petroleum refineries with a combined throughput capacity of approximately 3.2 million barrels per day; and 12 ethanol plants with a combined ethanol production capacity of approximately 1.6 billion gallons per year. It sells its refined products through wholesale rack and bulk markets; and through approximately 7,000 outlets under the Valero, Beacon, Diamond Shamrock, Shamrock, Ultramar, and Texaco brands. The company also produces and sells ethanol, dry distiller grains, syrup, and inedible corn oil primarily to animal feed customers. In addition, it owns and operates crude oil and refined petroleum products pipelines, terminals, tanks, marine docks, truck rack bays, and other logistics assets; and owns and operates a plant that processes animal fats, used cooking oils, and inedible distillers corn oils into renewable diesel. The company was formerly known as Valero Refining and Marketing Company and changed its name to Valero Energy Corporation in August 1997. Valero Energy Corporation was founded in 1980 and is headquartered in San Antonio, Texas.

NYSE ended the session with Valero Energy sliding 8.09% to $127.32 on Tuesday while NYSE dropped 0.73% to $15,374.11.

Earnings Per Share

As for profitability, Valero Energy has a trailing twelve months EPS of $-0.69.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 54.58%.

More news about Valero Energy.

8. United Rentals (URI) – -8.07%

United Rentals, Inc., through its subsidiaries, operates as an equipment rental company. It operates in two segments, General Rentals and Specialty. The General Rentals segment rents general construction and industrial equipment includes backhoes, skid-steer loaders, forklifts, earthmoving equipment, and material handling equipment; aerial work platforms, such as boom and scissor lifts; and general tools and light equipment comprising pressure washers, water pumps, and power tools for construction and industrial companies, manufacturers, utilities, municipalities, homeowners, and government entities. The specialty segment rents specialty construction products, including trench safety equipment consists of trench shields, aluminum hydraulic shoring systems, slide rails, crossing plates, construction lasers, and line testing equipment for underground work; power and heating, ventilating, and air conditioning equipment, such as portable diesel generators, electrical distribution equipment, and temperature control equipment; fluid solutions equipment for fluid containment, transfer, and treatment; and mobile storage equipment and modular office space. This segment serves construction companies involved in infrastructure projects, and municipalities and industrial companies. It also sells aerial lifts, reach forklifts, telehandlers, compressors, and generators; construction consumables, tools, small equipment, and safety supplies; and parts for equipment that is owned by its customers, as well as provides repair and maintenance services. The company sells used equipment through its sales force, brokers, website, at auctions, and directly to manufacturers. The company operates a network of 1,521 rental locations in the United States, Canada, Europe, Australia, and New Zealand. United Rentals, Inc. was incorporated in 1997 and is headquartered in Stamford, Connecticut.

NYSE ended the session with United Rentals dropping 8.07% to $357.68 on Tuesday while NYSE slid 0.73% to $15,374.11.

Earnings Per Share

As for profitability, United Rentals has a trailing twelve months EPS of $12.69.

PE Ratio

United Rentals has a trailing twelve months price to earnings ratio of 28.19. Meaning, the purchaser of the share is investing $28.19 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.25%.

Yearly Top and Bottom Value

United Rentals’s stock is valued at $357.68 at 17:32 EST, way under its 52-week high of $481.99 and way higher than its 52-week low of $230.54.

Sales Growth

United Rentals’s sales growth is 24.5% for the present quarter and 23.9% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 18.7%, now sitting on 11.64B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, United Rentals’s stock is considered to be oversold (<=20).

More news about United Rentals.

9. Inovio Pharmaceuticals (INO) – -7.98%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals dropping 7.98% to $0.72 on Tuesday, following the last session’s downward trend. NASDAQ fell 0.52% to $12,126.33, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.073.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.27%.

More news about Inovio Pharmaceuticals.

10. Nucor Corporation (NUE) – -7.34%

Nucor Corporation manufactures and sells steel and steel products. The company's Steel Mills segment produces hot-rolled, cold-rolled, and galvanized sheet steel products; plate steel products; wide-flange beams, beam blanks, and H-piling and sheet piling products; and bar steel products, such as blooms, billets, concrete reinforcing and merchant bars, and special bar quality products. It also engages in the steel trading and rebar distribution businesses. This segment sells its products to steel service centers, fabricators, and manufacturers in the United States, Canada, and Mexico. Its Steel Products segment offers hollow structural section steel tubing products, electrical conduits, steel racking, steel joists and joist girders, steel decks, fabricated concrete reinforcing steel products, cold finished steel products, steel fasteners, metal building systems, insulated metal panels, steel grating and expanded metal products, and wire and wire mesh products primarily for use in nonresidential construction applications. This segment also engages in the piling distribution business. The company's Raw Materials segment produces direct reduced iron (DRI); brokers ferrous and nonferrous metals, pig iron, hot briquetted iron, and DRI; supplies ferro-alloys; and processes ferrous and nonferrous scrap metal, as well as engages in the natural gas drilling operations. This segment sells its ferrous scrap to electric arc furnace steel mills and foundries for manufacturing process; and nonferrous scrap metal to aluminum can producers, secondary aluminum smelters, steel mills and other processors, and consumers of various nonferrous metals. It serves agriculture, automotive, construction, energy and transmission, oil and gas, heavy equipment, infrastructure, and transportation industries through its in-house sales force; and internal distribution and trading companies. Nucor Corporation was incorporated in 1958 and is based in Charlotte, North Carolina.

NYSE ended the session with Nucor Corporation falling 7.34% to $143.11 on Tuesday while NYSE slid 0.73% to $15,374.11.

Earnings Per Share

As for profitability, Nucor Corporation has a trailing twelve months EPS of $5.39.

PE Ratio

Nucor Corporation has a trailing twelve months price to earnings ratio of 26.56. Meaning, the purchaser of the share is investing $26.56 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 47.29%.

Volatility

Nucor Corporation’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.48%, a negative 0.72%, and a positive 1.85%.

Nucor Corporation’s highest amplitude of average volatility was 1.48% (last week), 2.08% (last month), and 1.85% (last quarter).

Yearly Top and Bottom Value

Nucor Corporation’s stock is valued at $143.11 at 17:32 EST, way below its 52-week high of $187.90 and way higher than its 52-week low of $100.13.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nucor Corporation’s stock is considered to be oversold (<=20).

More news about Nucor Corporation.

Stay up to date with our winners and losers daily report